Loading...
Loading...
Thermo Fisher Scientific Inc.
announced today that it intends to
offer dollar-denominated senior notes. The company also announced that it
intends to conduct an offering of euro-denominated senior notes later in the
fourth quarter of 2014, subject to market conditions. There can be no
assurance as to whether or when the company may complete either the
dollar-denominated notes offering or any euro-denominated notes offering.
Thermo Fisher intends to use the net proceeds of the dollar-denominated
offering principally to repay outstanding indebtedness, including the $400
million aggregate principal amount of its 3.25% senior notes due 2014 that
mature on November 20, 2014. The net proceeds of any euro-denominated offering
would also be used principally to repay outstanding indebtedness.
The joint book-running managers for the dollar-denominated notes offering are
Merrill Lynch, Pierce, Fenner & Smith Incorporated and Mitsubishi UFJ
Securities (USA), Inc.
The issuer has filed a registration statement (including a prospectus) with
the U.S. Securities and Exchange Commission (SEC) for the dollar-denominated
offering to which this communication relates. Before you invest, you should
read the prospectus in that registration statement and other documents the
issuer has filed with the SEC for more complete information about the issuer
and this offering. You may get these documents for free by visiting EDGAR on
the SEC website at www.sec.gov. Alternatively, Thermo Fisher, the underwriters
or any dealer participating in this offering will arrange to send you the
prospectus if you request it by calling Merrill Lynch, Pierce, Fenner & Smith
Incorporated toll-free at 1-800-294-1322; or by calling Mitsubishi UFJ
Securities (USA), Inc. toll-free at 1-877-649-6848. If the company makes an
offering of euro-denominated notes, it will file a prospectus and prospectus
supplement related to such offering with the SEC, which prospective investors
should read, that will provide information about how to obtain the prospectus
and prospectus supplement.
This press release shall not constitute an offer to sell or the solicitation
of an offer to buy the dollar-denominated notes or the euro-denominated notes,
nor shall there be any offer, solicitation or sale of dollar-denominated notes
or euro-denominated notes in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such jurisdiction.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in